In This Section

Program

notice of change to virtual meeting

Please see meeting overview for important information
Access the Webex Webcast of the Conference Here

MONDAY, MARCH 23, 2020

Tuesday, march 24, 2020

Monday, March 23, 2020

Welcome and Opening Remarks
9-9:15 A.M.

Hugh Auchincloss, National Institute of Allergy and Infectious Diseases, Rockville, Maryland

Keynote Lecture
9:15-9:45 A.M.

Understanding the immunopathogenesis of irAEs and the prospects for targeted therapy
Leonard H. Calabrese, Cleveland Clinic, Cleveland, Ohio      

SESSION I: RHEUMATIC TOXICITIES 
Session Moderator: Leonard H. Calabrese, Cleveland Clinic, Cleveland, Ohio
9:45-10:30 A.M.

Rheumatologic immune-related adverse events: Not our classic autoimmune diseases
Laura C. Cappelli, Johns Hopkins University School of Medicine, Baltimore, Maryland

Rheumatic toxicities associated with immune checkpoint inhibitors: The severity of myositis
Yves Allenbach, Sorbonne University, Paris, France

Seeing is believing: Imaging modalities in rheumatologic immune-related adverse events
Sarthak Gupta, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland

Panel Discussion
10:30-11:00 A.M.

Break
11:00-11:30 A.M.
Session II: Infectious Diseases
Session Moderator: Virginia Sheikh, U.S. Food and Drug Administration, Silver Spring, Maryland
11:30 A.M.-12:15 P.M.

Effects of immune checkpoint blockade on HIV latency 
Rafick-Pierre Sékaly, Case Western Reserve University, Cleveland, Ohio

Preclinical TB work in Macaques 
Dan Barber, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland

PD-1 inhibitors for the treatment of progressive multifocal leukoencephalopathy
Irene Cortese, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland

Panel Discussion
12:15-12:45 P.M.

Lunch Break
12:45-2 p.m.
Session III: Role of the Microbiome
Session Moderator: Giorgio Trinchieri, National Cancer Institute, Bethesda, Maryland
2:00-2:45 p.m.

The role of the gut-tumor axis in tumorigenesis
Florencia McAllister, MD Anderson Cancer Center, Houston, Texas

Treatment of refractory melanoma patients with fecal microbiota transplants and immunotherapy
Gal Markel, Sheba Medical Center, Tel Aviv, Israel

Manipulating the microbiome to treat inflammatory cardiomyopathy
Burkhard Ludewig, Kantonsspital St. Gallen, St. Gallen, Switzerland

Panel Discussion
2:45-3:15 P.M.

Session IV:Predictive Biomarkers  
Session Moderator: Douglas B. Johnson, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
3:15-4:00 P.M.

Characterizing toxicities of immune checkpoint inhibitors
Douglas B. Johnson, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

ChDefining the features of T cell responses to tumor and self-antigens as predictors of response to checkpoint inhibitor therapy
Jane Buckner, Benaroya Research Institute, Seattle, Washington

Statistical considerations for evaluating biomarkers for irAEs
Lisa McShane, National Cancer Institute, Bethesda, Maryland 

Panel Discussion
4:00-4:30 P.M.

Tuesday, March 24, 2020

Welcome and keynote Lecture
9-9:45 a.m.

Norman “Ned” Sharpless, National Cancer Institute, Bethesda, Maryland

Keynote Lecture

Immune checkpoint blockade in cancer therapy: at the interface between anti-tumor and anti-self immunity
Suzanne Topalian, Johns Hopkins University School of Medicine, Baltimore, Maryland

break
9:45-10:05
Session V: iraes resulting from combination therapies
Session Moderator: Julie Brahmer, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
10:05-10:50 a.m.

Differentiation of dermatologic irAEs for patients on combination therapies: A consultant’s perspective
Mario E. Lacouture, Memorial Sloan Kettering Cancer Center, New York, New York

Differentiating between irAEs and other AEs in combination therapies
Lilian L. Siu, Princess Margaret Cancer Centre, Toronto, Canada

irAEs from RT + ICI
Silvia Formenti, Weill Cornell Medicine, New York, New York

Panel Discussion
10:50-11:30 A.M.

Lunch Break
11:30 a.m.-12:45 p.m.
Session VI: Nontraditional Nonclinical Models
Session Moderator: Kristina Howard, U.S. FOOD AND DRUG ADMINISTRATION, Silver Spring, Maryland
12:45-1:45 P.M.

Wild mouse microbiota in preclinical research
Barbara Rehermann, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland

Programmable bacteria for cancer
Tal Danino, Columbia University, New York, New York

A better HCC model for immunotherapy, in woodchucks?
Minhyung Kim, Roswell Park Comprehensive Cancer Center, Buffalo, New York

Canine clinical trials
Melissa Renee Chambers, University of Alabama at Birmingham, Birmingham, Alabama

Panel Discussion
1:45-2:15 P.M.

Session VII: Multidisciplinary Treatment Models
Session Moderator: nicole R. Leboeuf, Dana-Farber Cancer Institute, Boston, Massachusetts
2:15-3:20 p.m.

Severe Immunotherapy Complications (SIC) Service: A model integrating clinical care and clinical-  translational research
Kerry Reynolds, Massachusetts General Hospital Cancer Center, Boston, Massachusetts and
Chloe Villani, Massachusetts General Hospital/Broad Institute, Boston, Massachusetts  

A multidisciplinary immune-related toxicity team and prospective clinical trials for irAEs
Jarushka Naidoo, Johns Hopkins School of Medicine, Baltimore, Maryland

Management of immune checkpoint inhibitor-related GI toxicity
Yinghong “Mimi” Wang, MD Anderson Cancer Center, Houston, Texas

Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events
David Kozono, Dana-Farber Cancer Institute, Boston, Massachusetts

Panel Discussion
3:20-4:00 P.M.

Concluding Remarks
4 p.m.